The president-elect considered that the 94.5% efficiency is “encouraging” and thanked scientists and doctors.
The president-elect of the United States, Joe Biden, once again differentiated himself from Donald Trump and celebrated the efficacy announced by Moderna’s vaccine against the coronavirus, although he asked the population to maintain care until its results are confirmed and can be applied en masse. .
While the North American magnate continues to question the triumph of the Democrat and maintains the allegations of fraud, Biden addresses society as the new president.
“Today’s news about a second vaccine is one more reason to feel hopeful. What was true with the first vaccine is still true with the second: we are still months away. Until then, Americans should continue to practice social distancing and wearing chinstraps to control the virus, “Biden wrote from his Twitter account.
Then he added: “Once again, I congratulate the brilliant women and men who produced this breakthrough and who brought us one step closer to defeating this virus. I am also grateful for the frontline workers who are still facing the virus throughout the entire year. day”.
For his part, Trump returned to the charge from Twitter to insist on proclaiming himself the winner of the elections and accused the media to “promote” the Democratic candidate to the Presidency early.
“Why does the fake news media continually assume that Joe Biden will rise to the presidency, without even allowing our side to show, which we are preparing to do, how shattered and violated our great Constitution has been in the 2020 election? “, asked the republishing leader.
The American company Moderna announced on Monday that its experimental vaccine against the coronavirus has an efficacy of 94.5%, in a trial involving 30,000 volunteers and that it is in phase 3.
“The independent and designated Data Security Monitoring Board for the study of Phase 3 of mRNA-1273, its candidate vaccine against Covid-19, informed Moderna that the trial met the statistical criteria pre-specified in the efficacy study protocol, with a vaccine efficacy of 94.5%, “the statement said.
As reported by the company, “the primary endpoint of the phase 3 study is based on the analysis of confirmed and adjudicated Covid-19 cases starting two weeks after the second dose of vaccine.”
The announcement comes a week after Pfizer, whose vaccine was 90% effective, and days after Russia’s Sputnik V celebrated 92% success.